Navigation Links
Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin

Investigational cancer drug Pertuzumab shows promising results in advanced breast cancer when combined with Herceptin Phase III development initiated

BASEL, Switzerland, June 4, 2007-Early clinical results from Roche's trial of the exciting new cancer medicine pertuzumab, a HER dimerisation inhibitor, show substantial anti-tumour activity in patients with pre-treated HER2 positive breast cancer, when combined with Herceptin. The study showed that one in five patients responded to pertuzumab treatment and one in five also had stabilization of their disease lasting 6 months or more. The results are particularly promising, as the benefits were seen in patients with late stage cancer, whose options for further treatment are limited.

"This is potentially good news for patients whose HER2 positive breast cancer is not responding to current treatments," commented Dr Jose Baselga, lead investigator, Vall d'Hebron University Hospital, Barcelona, Spain. "We are encouraged by the initial results from this trial and are continuing to further recruit patients into the second stage of the study."

The phase II study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, investigated the combination of two of Roche's HER2 targeted agents, pertuzumab and Herceptin, in patients with HER2 positive metastatic breast cancer whose disease had progressed during treatment with Herceptin plus chemotherapy (1).

Pertuzumab is the first in a new innovative class of targeted agents known as HER dimerization inhibitors (HDIs). The drug inhibits the 'pairing' or dimerization of the protein HER2 with other HER family receptors (HER1, HER2, HER3, and HER4). This interaction is believed to play an important role in the growth and formation of several different cancer types. Pertuzumab in combination adds to the activity of Herceptin due to its different mode of action. "The positive results f
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... , The new Dompé website ... concerning the biopharmaceutical Group,s national and international clinical research activities ... recently launched institutional website that is receiving accolades from all ... new chapter in the fascinating story of Drug Discovery   ... hub on the world of clinical research, ranging from information ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today reported ... September 30, 2009. , For the third quarter of 2009, ... per share, compared to a net loss of $37.7 million, ... Weighted average shares outstanding for the third quarters of 2009 ...
... 2 The owner and operator of a Houston-area ... defrauding the Medicare program, announced Assistant Attorney General of ... Johnson of the Southern District of Texas and Daniel ... & Human Services (HHS). , Noel Wayne Jhagroo, 47, ...
Cached Medicine Technology:Rigel Announces Third Quarter 2009 Financial Results 2Rigel Announces Third Quarter 2009 Financial Results 3Rigel Announces Third Quarter 2009 Financial Results 4Rigel Announces Third Quarter 2009 Financial Results 5Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3
(Date:12/22/2014)... At the annual National League ... San Antonio, esteemed experts and thought leaders will ... in the way of successful organizational performance: resistance, ... faculty development opportunity is made possible through the ... to assist nurse educators to advance to leadership ...
(Date:12/21/2014)... 2014 In this report, the ... power source, product, and application. The market, by ... pneumatic instruments. By product, the market covers the ... The handpieces market is further subdivided into drills, ... laparoscopic instruments, shavers, wire/pin drivers, and others. Moreover, ...
(Date:12/21/2014)... Weddingshe.com, an outstanding online supplier of wedding dresses and ... selection of Cocktail Dresses for the winter 2014. All ... fashion trends. , “We take pride in ... All of them are offered at greatly discounted rates, ... effort to offer a nice shopping experience for global ...
(Date:12/21/2014)... 21, 2014 Khanna Vision Institute is ... at the Aspen Helicopters holiday event for underprivileged kids. ... with sleigh, flown by an aspen helicopter pilot. In ... Santa with sleigh was visible.(please see accompanying video). Helicopter ... Dr.Khanna has helped many pilots with Pi in eye ...
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring ... of 1,000 new designs in this collection, and all ... , AngelWeddingDress.com promises to provide the most ... essentials while many fashion trends come and go. If ... team at AngelWeddingDress.com is ready to assist. , ...
Breaking Medicine News(10 mins):Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2
... by aiding in senior health and ... ... in market research for the health insurance industry, today,announced the release of ... and over population. SrHRA provides,proven health risk stratification measures based on self-reported,information ...
... ... benefits plans, COLUMBIA, S.C., Jan. 9 One of ... and a clearer message.,Colonial Life & Accident Insurance Company today ... who the company is and what it,does., (Logo: ...
... Expected results include higher quality care, increased ... Group Health Incorporated (GHI) and,Health Plan of New York ... first of its kind in New York, that will provide ... to become Medical,Home Practices. GHI and HIP see this as ...
... Diego, January 8, 2008 ?Eating out instead of cooking ... the American diet. Americans face a large variety of ... out. Do the choices of available restaurants matter ... the February 2008 issue of the American Journal of ...
... could improve understanding of irritable bowel syndrome and lead ... News) -- Women with irritable bowel syndrome anticipate and ... new study suggests. , The University of California, ... effectively switch off a pain modulation mechanism in the ...
... Reduce Stiffness for Better Health with,Innovative ,Sleep and ... FORT LAUDERDALE, Fla., Jan. 9 Contour ... people implement an,ergonomic makeover into their life for ... well being. By aligning the body, relieving,pressure points ...
Cached Medicine News:Health News:DSS Research Announces Senior Health Risk Assessment Tool 2Health News:New Colonial Life Brand Clarifies Company's Strengths 2Health News:New Colonial Life Brand Clarifies Company's Strengths 3Health News:GHI and HIP Launch Pilot Medical Home Network Project with Support from Commonwealth Fund 2Health News:GHI and HIP Launch Pilot Medical Home Network Project with Support from Commonwealth Fund 3Health News:Eating out can have both positive and negative impact on obesity 2Health News:Women With IBS Unable to Switch Off Pain Response 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: